New perspectives on the treatment of mycobacterial infections using antibiotics

• Published in: Applied microbiology and biotechnology Vol. 104; no. 10; pp. 4197 - 4209
• Main Authors: He, Yile, Fan, Aili, Han, Meng, Zhang, Yihan, Tong, Yigang, Zheng, Guojun, Zhu, Shaozhou
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2020; Springer; Springer Nature B.V
• Subjects: Antibiotics; Antitubercular agents; Antitubercular Agents - pharmacology; Antitubercular Agents - therapeutic use; Bacterial infections; Bioinformatics; Biomedical and Life Sciences; Biotechnology; Care and treatment; Clinical Trials as Topic; Computational Biology; Development strategies; Drug development; Drug discovery; Drug resistance; Drug resistance in microorganisms; Drugs; Health aspects; Homeopathy; Humans; Infectious diseases; Life Sciences; Materia medica and therapeutics; Microbial Genetics and Genomics; Microbiology; Mini-Review; Multidrug resistance; multiple drug resistance; Mycobacterium tuberculosis; Mycobacterium tuberculosis - drug effects; pathogens; Patient compliance; phage therapy; Phages; Pharmaceutical industry; R&D; Research & development; research and development; Sustainable development; synthetic biology; Therapeutics; Tuberculosis; Tuberculosis - drug therapy; Tuberculosis - microbiology; Tuberculosis, Multidrug-Resistant - drug therapy; Lassomycin; Teixobactin; Anti-TB; Natural products; Phage therapy; Synthetic biology; Genome mining; Mycobacterium tuberculosis

More than 100 years have passed since the discovery of Mycobacterium tuberculosis , in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owin...